Belite Bio (BLTE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-40.0M
Net Income
-36.1M
EPS (Diluted)
-$1.18
Balance Sheet Metrics
Total Assets
152.1M
Total Liabilities
6.3M
Shareholders Equity
145.8M
Debt to Equity
0.04
Cash Flow Metrics
Operating Cash Flow
-30.5M
Free Cash Flow
-29.4M
Revenue & Profitability Trend
Belite Bio Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 40.0M | 31.7M | 12.8M | 9.8M | 5.7M |
| Operating Income | -40.0M | -31.7M | -12.8M | -9.8M | -5.7M |
| Pre-tax Income | -36.1M | -31.6M | -12.6M | -9.7M | -5.8M |
| Income Tax | 6.0K | 9.0K | 0 | 0 | 1.0K |
| Net Income | -36.1M | -31.6M | -12.6M | -9.7M | -5.8M |
| EPS (Diluted) | -$1.18 | -$1.19 | -$0.63 | -$0.40 | -$0.24 |
Income Statement Trend
Belite Bio Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 147.1M | 89.9M | 42.8M | 17.4M | 25.7M |
| Non-Current Assets | 5.1M | 4.7M | 1.5M | 917.0K | 73.0K |
| Total Assets | 152.1M | 94.6M | 44.3M | 18.3M | 25.7M |
| Liabilities | |||||
| Current Liabilities | 6.0M | 3.6M | 2.1M | 1.6M | 972.0K |
| Non-Current Liabilities | 261.0K | 578.0K | 668.0K | 31.8M | 31.8M |
| Total Liabilities | 6.3M | 4.2M | 2.8M | 33.4M | 32.8M |
| Equity | |||||
| Total Shareholders Equity | 145.8M | 90.4M | 41.5M | -15.1M | -7.0M |
Balance Sheet Composition
Belite Bio Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -36.1M | -31.6M | -12.6M | -9.7M | -5.8M |
| Operating Cash Flow | -30.5M | -27.7M | -11.1M | -8.1M | -4.4M |
| Investing Activities | |||||
| Capital Expenditures | -116.0K | -63.0K | -394.0K | -56.0K | -20.0K |
| Investing Cash Flow | -110.5M | -63.0K | -394.0K | -56.0K | -20.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 41.9M | 54.0M | 37.0M | -815.0K | 28.0M |
| Free Cash Flow | -29.4M | -29.9M | -11.9M | -7.5M | -4.5M |
Cash Flow Trend
Belite Bio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-52.58
Forward P/E
-63.00
Price to Book
12.45
PEG Ratio
-63.00
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-33.43%
Return on Assets
-22.23%
Financial Health
Current Ratio
25.98
Debt to Equity
0.00
Beta
-1.44
Per Share Data
EPS (TTM)
-$1.36
Book Value per Share
$4.86
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| blte | 2.0B | -52.58 | 12.45 | -33.43% | 0.00% | 0.00 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.